Lenvervimab

From WikiMD's Wellness Encyclopedia

Lenvervimab is a monoclonal antibody designed for the treatment of COVID-19. It was developed by Celltrion, a South Korean biopharmaceutical company. Lenvervimab is also known by its developmental code name, CT-P59.

Mechanism of Action[edit | edit source]

Lenvervimab works by binding to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This mechanism of action is similar to other monoclonal antibodies used in the treatment of COVID-19.

Clinical Trials[edit | edit source]

Lenvervimab has undergone Phase I, Phase II, and Phase III clinical trials. The results from these trials have shown that Lenvervimab is effective in reducing the severity of COVID-19 symptoms and the duration of the disease.

Approval[edit | edit source]

In February 2022, Lenvervimab was granted conditional approval by the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of COVID-19.

Side Effects[edit | edit source]

As with all medications, Lenvervimab can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and diarrhea.

See Also[edit | edit source]

Lenvervimab Resources

Contributors: Prab R. Tumpati, MD